BACKGROUND: Rhinoviruses are important triggers of pulmonary exacerbations and possible contributors to long-term respiratory morbidity in cystic fibrosis (CF), but mechanisms leading to rhinovirus-induced CF exacerbations are poorly understood. It is hypothesised that there is a deficient innate immune response of the airway epithelium towards rhinovirus infection in CF. METHODS: Early innate immune responses towards rhinoviruses (RV-16, major-type and RV-1B, minor-type) in CF and non-CF bronchial epithelial cell lines and primary nasal and bronchial epithelial cells from patients with CF (n=13) and healthy controls (n=24) were studied. RESULTS: Rhinovirus RNA expression and virus release into supernatants was increased more than tenfold in CF cells compared with controls. CF cells expressed up to 1000 times less interferon (IFN) type I (β) and type III (λ) mRNA and produced less than half of IFN-β and IFN-λ protein compared with controls. In contrast, interleukin 8 production was not impaired, indicating a selective deficiency in the innate antiviral defence system. Deficient IFN production was paralleled by lower expression of IFN-stimulated genes including myxovirus resistance A, 2',5'-oligoadenylate synthetase, viperin and nitric oxide synthase 2. Addition of exogenous type I and III IFNs, particularly IFN-β, restored antiviral pathways and virus control in CF cells, underscoring the crucial role of these molecules. CONCLUSIONS: This study describes a novel mechanism to explain the increased susceptibility of patients with CF to rhinovirus infections. A profound impairment of the antiviral early innate response in CF airway epithelial cells was identified, suggesting a potential use of IFNs in the treatment of rhinovirus-induced CF exacerbations.
BACKGROUND: Rhinoviruses are important triggers of pulmonary exacerbations and possible contributors to long-term respiratory morbidity in cystic fibrosis (CF), but mechanisms leading to rhinovirus-induced CF exacerbations are poorly understood. It is hypothesised that there is a deficient innate immune response of the airway epithelium towards rhinovirus infection in CF. METHODS: Early innate immune responses towards rhinoviruses (RV-16, major-type and RV-1B, minor-type) in CF and non-CF bronchial epithelial cell lines and primary nasal and bronchial epithelial cells from patients with CF (n=13) and healthy controls (n=24) were studied. RESULTS: Rhinovirus RNA expression and virus release into supernatants was increased more than tenfold in CF cells compared with controls. CF cells expressed up to 1000 times less interferon (IFN) type I (β) and type III (λ) mRNA and produced less than half of IFN-β and IFN-λ protein compared with controls. In contrast, interleukin 8 production was not impaired, indicating a selective deficiency in the innate antiviral defence system. Deficient IFN production was paralleled by lower expression of IFN-stimulated genes including myxovirus resistance A, 2',5'-oligoadenylate synthetase, viperin and nitric oxide synthase 2. Addition of exogenous type I and III IFNs, particularly IFN-β, restored antiviral pathways and virus control in CF cells, underscoring the crucial role of these molecules. CONCLUSIONS: This study describes a novel mechanism to explain the increased susceptibility of patients with CF to rhinovirus infections. A profound impairment of the antiviral early innate response in CF airway epithelial cells was identified, suggesting a potential use of IFNs in the treatment of rhinovirus-induced CF exacerbations.
Authors: Qun Wu; Linda F van Dyk; Di Jiang; Azzeddine Dakhama; Liwu Li; Steven R White; Ashley Gross; Hong Wei Chu Journal: Virology Date: 2013-08-30 Impact factor: 3.616
Authors: Dhara A Patel; Yingjian You; Guangming Huang; Derek E Byers; Hyun Jik Kim; Eugene Agapov; Martin L Moore; R Stokes Peebles; Mario Castro; Kaharu Sumino; Adrian Shifren; Steven L Brody; Michael J Holtzman Journal: J Allergy Clin Immunol Date: 2014-09-09 Impact factor: 10.793
Authors: Gang Chen; Thomas R Korfhagen; Christopher L Karp; Soren Impey; Yan Xu; Scott H Randell; Joseph Kitzmiller; Yutaka Maeda; Hans Michael Haitchi; Anusha Sridharan; Albert P Senft; Jeffrey A Whitsett Journal: Am J Respir Crit Care Med Date: 2014-02-01 Impact factor: 21.405
Authors: Lucy Bianca Woodman; Wing Yan Heidi Wan; Roberta Milone; Ken Grace; Ana Sousa; Rick Williamson; Christopher Edward Brightling Journal: Chest Date: 2013-06 Impact factor: 9.410
Authors: Ji Heui Kim; You Sun Kim; Gye Song Cho; Nam Hee Kim; Chang Hoon Gong; Bong Jae Lee; Yong Ju Jang Journal: Allergy Asthma Immunol Res Date: 2015-05-26 Impact factor: 5.764
Authors: M R Edwards; N Regamey; M Vareille; E Kieninger; A Gupta; A Shoemark; S Saglani; A Sykes; J Macintyre; J Davies; C Bossley; A Bush; S L Johnston Journal: Mucosal Immunol Date: 2012-12-05 Impact factor: 7.313